Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06628908 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
A Phase 3 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT06628908 is a Phase 3 study of Diabetic Peripheral Neuropathic Pain that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 1,100 participants, above the 280-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (293% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT06628908, a Phase 3 study of Diabetic Peripheral Neuropathic Pain, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Conditions Studied
Interventions
- DRUG Suzetrigine
- DRUG Pregabalin
- DRUG Placebo (matched to SUZ)
- DRUG Placebo (matched to Pregabalin)
Study Locations (20)
California
- Neuro-Pain Medical Center - Fresno
- Long Beach Research Institute - Long Beach
- Angel City Research, Inc - Los Angeles
- Empire Clinical Research - Pomona
- Clinical Trials Research - Sacramento
- Velocity Clinical Research, San Bernardino - San Bernardino
- SCLA Management - Pain Management and Injury Relief - Thousand Oaks
- Diablo Clinical Research (DCR) - Walnut Creek
Florida
- Accel Research - Deland - DeLand
- AMR-Miami - Doral
- AMR Fort Myers (The Clinical Study Center) - Fort Myers
- Velocity Clinical Research - Hallandale Beach - Hallandale
- CNS Healthcare - Jacksonville - Jacksonville
Alabama
- Pinnacle Research Group, LLC - Anniston
- Synexus Clinical Research - Birmingham - Birmingham
- AMR Daphne, AL - Daphne
Arizona
- Synexus Clinical Research - Phoenix Central - Phoenix
- Scottsdale Clinical Trials - Scottsdale
Colorado
- Velocity Clinical Research - Denver - Englewood
District of Columbia
- Velocity Clinical Research - Washington DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06628908
The ClinicalTrials.gov registry entry for NCT06628908 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 280-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (293% higher). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 4 interventions - of which Suzetrigine is the first listed.
NCT06628908 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06628908 about?
NCT06628908 is a clinical study titled "Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy". The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
What is the current status of trial NCT06628908?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2024-10-01. Estimated completion is 2027-05-31.
What conditions does trial NCT06628908 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT06628908?
The interventions under investigation include: Suzetrigine (DRUG), Pregabalin (DRUG), Placebo (matched to SUZ) (DRUG), Placebo (matched to Pregabalin) (DRUG).
Who is sponsoring clinical trial NCT06628908?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06628908 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
ACTIVE NOT RECRUITING · Phase 3
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.